UKEMS 2023 -- The OECD 488 test guideline (TG488) on Transgenic Rodent Somatic and Germ Cell Gene Mutation Assays was first adopted in July 2011 and has been revised periodically in July 2013, June 2020 and most recently in June 2022. This guideline describes the use of a variety of transgenic rodent models to reliably measure gene mutations in vivo.
UKEMS 2023 -- The in vivo phosphatidylinositol glycan class A (Pig-a) gene mutation assay is based on the endogenous X-linked Pig-a gene, which codes for an N-acetyl glucosamine transferase that is involved in the biosynthesis of glycosyl phosphatidyl inositol (GPI) anchor for tethering a variety of mammalian cell surface protein markers.
UKEMS 2023 -- The Bhas 42 cell promoter transformation assay is a sensitive short-term system for predicting chemical carcinogenicity related to transformation promotion activity. Bhas 42 cells were established from BALB/c 3T3 A31-1-1 cells by the transfection of v‑Ha‑ras gene.
Leverage decades of specialized experience, operational excellence and a broad spectrum of discovery capabilities to gain decision-driving data to confidently advance your potentially life-changing drug candidate.
A Comprehensive, Customizable Genomic and Immune Profiling Solution - from Discovery through Commercialization. Your mission is to move across the drug development continuum with speed and efficiency. Our goal is to help you by delivering insight on emerging and actionable biomarkers targeted for drug development.
A leading cell therapy biotechnology company partnered with Labcorp for the development of its novel autologous chimeric antigen receptor (CAR) T-cell therapy for a variety of hematologic malignancies, from preclinical studies through registrational clinical trials to assess safety and efficacy.
Chimeric antigen receptor (CAR) T-cell therapies are effective immunotherapeutic tools for combating cancer with genetically modified cancer-specific receptors. The effectiveness of cancer treatment is likely to fuel the global market growth of CAR T-cell therapy in the years to come.
Explore our global immunology and immunotoxicology capabilities, customizable to meet your needs: From early biomarker discovery and preclinical toxicology in a range of species, all the way through to early and late-stage clinical trials.
Give your device a healthy start by gaining the experienced and knowledgeable advice and specialized testing your device or combination product demands. Gain the insights and clarity you need to move forward with greater confidence.
The preclinical stage of medical device development comes with a unique set of challenges. You need to determine that the materials that make up your device are safe and biologically compatible and that your prototype will perform the way you intend.
